Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,611.83
(
0.44%
)
US TECH 100
23,535.20
(
-0.02%
)
Dow Jones
46,669.88
(
0.36%
)
Brent Oil
106.88
(
-0.18%
)
Bitcoin
68,950.89
(
0.13%
)
News Focus
News Focus
Post# of 257366
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122852
Boards Moderated 8
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biomaven0 post# 109208

Thursday, 11/18/2010 3:21:20 PM

Thursday, November 18, 2010 3:21:20 PM

Post# of 257366
Today is the Denosumab PDUFA date for treatment (rather than prevention) of bone mets; the phase-3 trial in bone-met prevention is due to report data any day.

In the best case for EXEL, XL184 will still be several years behind Denosumab, assuming both make it to market in the bone-met-prevention indication.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today